IL-2-kill-Cancer Cell
Taking into account "the prognosis for recurrent bladder cancer which is poor, researchers at University Hospitals Case Medical Center are working to develop an immunotherapy for the disease that will stimulate the body's own natural defense mechanisms to cure the disease and prevent recurrence.
William Larchian, MD, urologic oncologist, the Urology Institute at University Hospitals Case Medical Center says that "What is interesting is that our bodies are capable of identifying, responding to, and killing tumor cells naturally". "We are developing a vaccination system to enhance this response and drive an effective immune response against existing and future bladder tumor cells in patients diagnosed with bladder cancer."
The enhanced IL-2 protein expression has been shown to successfully stimulate T-cell response and eliminate bladder tumors in a mouse model, particularly when followed by transfection with B7.1 gene. The addition of the B7.1 gene, which encodes an immune co-stimulatory molecule, enhanced T-cell production logarithmically and produced a 70% cure rate. The birth of new cancer cells was also prevented. Clinical translation of the research has been submitted for institutional review board approval at UH Case Medical Center.
.....read more
Source: http://www.dddmag.com/
Taking into account "the prognosis for recurrent bladder cancer which is poor, researchers at University Hospitals Case Medical Center are working to develop an immunotherapy for the disease that will stimulate the body's own natural defense mechanisms to cure the disease and prevent recurrence.
William Larchian, MD, urologic oncologist, the Urology Institute at University Hospitals Case Medical Center says that "What is interesting is that our bodies are capable of identifying, responding to, and killing tumor cells naturally". "We are developing a vaccination system to enhance this response and drive an effective immune response against existing and future bladder tumor cells in patients diagnosed with bladder cancer."
The enhanced IL-2 protein expression has been shown to successfully stimulate T-cell response and eliminate bladder tumors in a mouse model, particularly when followed by transfection with B7.1 gene. The addition of the B7.1 gene, which encodes an immune co-stimulatory molecule, enhanced T-cell production logarithmically and produced a 70% cure rate. The birth of new cancer cells was also prevented. Clinical translation of the research has been submitted for institutional review board approval at UH Case Medical Center.
.....read more
Source: http://www.dddmag.com/
